David Silberman
First SEC filing: March 18, 2026 · Latest: March 18, 2026
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 29, 2026 | CGEN | A | 26,000 | · | · | 26,000 Direct | · | Acquired | (price as of 2026-10-02) |
| July 29, 2026 | CGEN | A | 19,500 | · | · | 55,000 Direct | +54.93% | Acquired | (price as of 2026-10-02) |
| Jan. 4, 2024 | ORMP | A | 136,500 | · | · | 366,500 Direct | +59.35% | Acquired | (price as of 2026-10-02) |
| May 26, 2023 | ORMP | A | 24,500 | · | · | 230,000 Direct | +11.92% | Acquired | (price as of 2026-10-02) |
| April 17, 2023 | ORMP | A | 97,500 | · | · | 205,500 Direct | +90.28% | Acquired | (price as of 2026-10-02) |
| July 28, 2022 | ORMP | A | 39,000 | · | · | 108,000 Direct | +56.52% | Acquired | (price as of 2026-10-02) |
| Jan. 3, 2022 | ORMP | A | 32,000 | · | · | 32,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 3, 2022 | ORMP | A | 19,000 | · | · | 69,000 Direct | +38.00% | Acquired | (price as of 2026-10-02) |
| Sept. 1, 2021 | ORMP | A | 50,000 | · | · | 50,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Sept. 1, 2021 | ORMP | A | 50,000 | · | · | 50,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| July 29, 2026 | CGEN | Share Option (right to buy) | Ordinary Shares | $2.26 | July 29, 2036 | 26,000 | Acquired |
| Jan. 3, 2022 | ORMP | Stock Option (right to buy) | Common Stock | $13.89 | Jan. 3, 2032 | 32,000 | Acquired |
| Sept. 1, 2021 | ORMP | Stock Option (right to buy) | Common Stock | $20.19 | Sept. 1, 2031 | 50,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $156,070 | $62,027 | · | · | · | · | $41,434 | $536,711 |
| 2022 | $155,125 | $49,732 | · | $261,754 | · | · | $43,184 | $1,269,200 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.